Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months

Summary by MarketBeat
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%

1 Articles

MarketBeatMarketBeat
Center

Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months

Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Saturday, October 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Redwood City icon

Redwood City

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal